Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Why Is Autolus Therapeutics (NASDAQ:AUTL) Edging Up 8.33% Pre-Market Before Its Q3 Results?

As general background, a cell therapy company with one marketed product is valued on its sales ramp, gross margin and cash runway. Each quarter shows whether treatment centres are adding patients to AUCATZYL, an obecabtagene autoleucel therapy for adult B-cell acute lymphoblastic leukaemia. Guidance …

Vinay Lochav | 10 November 2026

Why Is Karyopharm Therapeutics (NASDAQ:KPTI) Tumbling 22.25% Pre-Market on Tuesday?

Key HighlightsKaryopharm Therapeutics (NASDAQ:KPTI) is indicated at USD 0.0311 pre-market on November 10, 2026, which is 22.25% below a calculated prior close of USD 0.0400.The company lodged Chapter 11 papers on November 2, 2026, supported by a USD 55 millionBankruptcyloan, with Ayrmid leading the …

Vinay Lochav | 10 November 2026

Why Has Jin Medical International (NASDAQ:ZJYL) Slipped 17.7% Before the Tuesday Open?

Key HighlightsJin Medical International (NASDAQ:ZJYL) was indicated at USD 3.25 before Tuesday's open on November 10, 2026, 17.7% under a calculated prior close of USD 3.95, after Monday's rise of USD 0.59 or 17.6%.Based on Monday's close, the company'sMarket Valuestood at USD 30.92 million …

Vinay Lochav | 10 November 2026

Why Has Adagio Medical Holdings (NASDAQ:ADGM) Dropped 15.62% Before the Tuesday Open?

No catalyst for the move has been confirmed in published coverage. Relevant background: on September 16, 2026 the company flagged its first treated patient in an IDE study for the vCLAS Ultra system, which targets ventricular tachycardia, and around September 23, 2026 it announced …

Vinay Lochav | 10 November 2026

Why Has Lakewood-Amedex (NASDAQ:LABT) Dropped 11% Before the Open on Tuesday?

No company release or filing dated November 9 or November 10, 2026 turned up in published coverage, so the cause of the decline is unknown. In general, nano-cap biotechs often move on a financing or at-the-market offering, a Nasdaq minimum bid price deficiency notice, …

Vinay Lochav | 10 November 2026

How Should Australia’s Five-Year Perinatal Death Figures Be Read?

Perinatal death counts were 2,744 in 2021, 2,739 in 2022 and 2,695 in 2023. They increased to 2,952 in 2024 before decreasing to 2,895 in 2025.

Sonal Goyal | 10 November 2026

What Do Australia’s 2025 Figures Show About Neonatal Deaths?

The published series records 745 neonatal deaths in 2021, 695 in 2022 and 660 in 2023. The count then increased to 719 in 2024 and 784 in 2025.

Sonal Goyal | 10 November 2026

How Did Australia’s Perinatal Death Figures Change in 2025?

The national total comprised 2,111 stillbirths and 784 neonatal deaths. Stillbirths decreased by 122, or 5.5%, from 2,233 in 2024. Neonatal deaths increased by 65, or 9.0%, from 719.

Sonal Goyal | 10 November 2026

Medibank Private Limited (ASX:MPL): What FY26 Revealed About Health Cover and Care Delivery

Medibank reported AUD 6.9 billion in total claims paid in FY26, while delivering almost AUD 300 million of additional value to customers during the year. The company said it was balancing rising healthcare costs against affordability considerations for policyholders. Claims payments and customer benefits …

Aditi Sarkar | 10 November 2026

nib Holdings (ASX:NHF): FY26 Insurance Growth and Claims Costs in Focus

For FY26, nib reported total income of AUD 3,854.8 million, up 6.2% year on year. InsuranceRevenueincreased 6.5% to AUD 3,685.7 million. Group underlying operating profit increased 9.1% to AUD 260.9 million, supported by performance across several insurance operations and improved productivity.Underlying Profitis a management …

Aditi Sarkar | 10 November 2026
Support

Hi! How can we help you today?

Loading…